Besides, the combination of NVP-CGM097 with other clinically available drugs such as 5-fluoroucracil, temozolomide, or everolimus (RAD001) showed additive antiproliferative effects in neuroendocrine tumor cell line GOT1 cells, in particular, the co-incubation with 5-fluoroucracil also increased p53 and p21 expression in an additive manner (41). The gene discussed is TP53; the disease is neuroendocrine neoplasm.